EUVIMEDEUVIMED entdecken
Crossref

Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs

Yiming Cheng iD, Shuyu Chu iD, Jie Pu, Min Chen, Kevin Hong, Paulo Maciag iD, Ivan Chan, Li Zhu iD, Akintunde Bello, Yan Li iD

Journal of Clinical Oncology · 10.12.2024 · 42 (35) · 4145-4152

DOI: 10.1200/jco.24.00349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2024. Verfasst von Yiming Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The advent of new therapeutic modalities highlighted deficiencies in the traditional maximum tolerated dose approach for oncology drug dose selection and prompted the Food and Drug Administration (FDA)'s Project Optimus initiative, which suggests that sponsors take a holistic approach, including efficacy, safety, and pharmacokinetic (PK) and pharmacodynamic data, in conjunction with integrated exposure-response (ER) analyses. However, this method comes with an inherent challenge of the collation of the multisource data. To address this issue, an ER-based clinical utility score (CUS) framework, combining benefit and risk into a single measurement, was developed. METHODS Model-predicted outcomes for each clinically relevant end point, informed by ER modeling, are converted to a CUS using a user-defined utility function. Thereafter, individual CUS is integrated into a single score with user-defined weighting for each end point. The user-defined weighting feature allows the user to incorporate expert knowledge/understanding into weighing the product's benefit versus risk profile. RESULTS To validate the framework, data were leveraged from over 50 oncology programs from 2019 to 2023 on the basis of FDA new drug application/biologics license application review packages and/or related literature studies. Five representative cases were selected for in-depth evaluation. Results showed that the optimal benefit-risk ratio (highest CUS) was consistently observed at PK exposures synonymous with recommended doses. A recurring theme across cases was a greater emphasis on safety over efficacy in oncology drug dose determination. CONCLUSION The ER-based CUS framework offers a strategic tool to navigate the complexities of dose selection in oncology programs. It serves as a pillar to the importance of integrative data analysis, aligning with the vision of Project Optimus , and demonstrates its potential in guiding dose optimization by balancing therapeutic benefits against risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsDose-Response Relationship, DrugHumansMaximum Tolerated DoseRisk AssessmentUnited StatesUnited States Food and Drug Administration

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ.
  • Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ.
  • Global Drug Development, Bristol Myers Squibb, Princeton, NJ.

ORCID-Profile: Yiming Cheng, Shuyu Chu, Paulo Maciag, Li Zhu, Yan Li

Zitieren

APA

Cheng, Y., Chu, S., Pu, J., Chen, M., Hong, K., Maciag, P., Chan, I., Zhu, L., Bello, A., & Li, Y. (2024). Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs. Journal of Clinical Oncology, 42(35), 4145-4152. https://doi.org/10.1200/jco.24.00349

Vancouver

Cheng Y, Chu S, Pu J, Chen M, Hong K, Maciag P, et al. Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs. Journal of Clinical Oncology. 2024;42(35):4145-4152. doi:10.1200/jco.24.00349

BibTeX
@article{Cheng2024,
  author = {Cheng, Yiming and Chu, Shuyu and Pu, Jie and Chen, Min and Hong, Kevin and Maciag, Paulo and Chan, Ivan and Zhu, Li and Bello, Akintunde and Li, Yan},
  title = {Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {35},
  pages = {4145--4152},
  doi = {10.1200/jco.24.00349}
}
Kostenlos starten →